Independent equity research
Is Sanofi S.A. (SAN.PA) a Buy, Hold or Sell?
Sanofi S.A. — our independent, AI-built valuation and rating, in brief.
BUY (accumulate)
12-mo fair value
€103.00
To fair value
+41%
By · report dated 2026-09-02 · fair value derived independently of the market price.
The thesis, in brief
Sanofi at 8.6x 2027E business EPS is priced for a Dupixent cliff that cannot begin before March 2031 and lands on roughly half-margin revenue since Regeneron takes half the profit; we are wrong if 2027 business EPS guides below EUR 8.60 or a US Dupixent biosimilar is cleared to launch before 2031
How we value it
We value Sanofi S.A. using Product-level FCF DCF on three Dupixent-cliff paths; forward P/E cross-check. The 12-month fair value is set from that intrinsic estimate first, then compared to the market to read the upside or downside — never anchored to the current price.
What the full report covers
- Business & moat + industry cycle
- Earnings quality & normalized EPS
- Returns on capital (ROIC vs WACC)
- Balance-sheet safety
- Two independent valuations (DCF + multiples)
- Bear / base / bull fair values
- Earnings-call analysis
- Insider activity & positioning
- Technicals (RSI / ADX)
- A falsifiable thesis
Read the full Sanofi S.A. report
The complete model, the scenarios, and every number behind the call — plus other names across the coverage. One subscription, cancel anytime.